Flagenase 400 (Metronidazole, Diiodohydroxyquinoline)
Active Ingredient: Metronidazole, Diiodohydroxyquinoline
Dosage: 400 mg / 200 mg
Route of Administration: Oral
Dosage Form: Suspension
Quantity per package: 120 ml
Availability: Out of stock
Flagenase 400 is a medication used to treat amoebiasis, infections of the gum and dental cavities, pelvic area infection, brain infection, lung infection, bone infections, stomach infections, intestinal infection, genital tract infection, blood infection, and other conditions.
Flagenase 400 is out of stock today but you can order similar antibiotics for treating infections here.
- Treatment of intraintestinal and extraintestinal amebiasis;
- Amebic liver abscess.
Dosage and administration
Children from 1 to 9 years: The dose will be calculated at the rate of 40 mg of metronidazole and diiodohydroxyquinoline per kg of weight/day divided into 3 doses per day for 10 days. The average dose is 125 to 250 mg (1 to 2 teaspoons every 8 hours). The maximum dose is 1.25 g / day divided in 3 doses. One teaspoon of 5 mL is = 125 mg of metronidazole and 100 mg of diiodohydroxyquinoline.
- Hypersensitivity to metronidazole;
- Consumption of alcohol, coumarin anticoagulants or disulfiram;
- History of blood dyscrasias;
- Hypersensitivity to any 8-hydroxyquinoline or preparations containing iodine;
- Previous liver damage.
In some cases, Flagenase 400 can cause epigastric pain, nausea, vomiting, diarrhea, oral mucositis, taste disorders, including metallic taste, anorexia, erythema, pruritus, flushing, hives, fever, angioedema, anaphylactic shock, peripheral sensory neuropathy, headache, seizures, vertigo, psychotic disorders including confusion, hallucinations, depressive mood, temporary visual disorders such as diplopia and myopia;
There is no specific antidote for Flagenase 400. The administration of diiodohydroxyquinoline in doses> at 2 g per day for long periods can be associated with significantly greater risks of producing toxic effects. The treatment of overdose with metronidazole and diiodohydroxyquinoline should be symptomatic, with general support measures and gastric lavage.
Concomitant use of metronidazole with warfarin inhibits its metabolism and may cause bleeding. Co-administration with disulfiram can cause acute psychosis or confusional state. Co-administration with ethanol palpitations causes tachycardia, nausea and vomiting. Barbiturates induce therapeutic failure by shortening the half-life of metronidazole, in which case the initial dose of metronidazole will be increased. The simultaneous use of cimetidine can decrease the hepatic metabolism of metronidazole, so it delays its elimination, increases its serum concentration and its potential toxicity. Phenobarbital increases the biotransformation of metronidazole, which decreases its half-life. Metronidazole inhibits the clearance of diphenylhydantoin by increasing its serum concentration.